Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Keeps you up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
![Essential](https://www.g2intelligence.com/wp-content/uploads/2023/11/Essential.png)
![62934_G2_Subscription Website Images_JL V1](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V1.png)
![Special-Report](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Report.png)
![62934_G2_Subscription Website Images_JL V12](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V12.png)
![Special-Analysis](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Analysis.png)
![Elite](https://www.g2intelligence.com/wp-content/uploads/2023/11/Elite.png)
Additional Business Intelligence Offerings
Lab Industry Advisor Subscriptions Include
![paper_magnifing_glass_512](https://www.g2intelligence.com/wp-content/uploads/2023/11/paper_magnifing_glass_512.png)
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
Many Not Getting Colorectal, Cervical Cancer Screenings
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Many adults are not getting recommended, routine screenings for cervical and colorectal cancer, according to the U.S. Centers for Disease Control and Prevention (CDC). Screening rates for...
Exosome Prostate Cancer Test Does Well in Clinical Validation Study
By Ron Shinkman, Editor, Laboratory Industry Report Massachusetts-based Exosome Diagnostics has released data from a clinical validation study suggesting its liquid biopsy test for prostate cancer patients could more accurately predict the presence of the disease...
Sequencing to Target Pancreatic Cancer Tx ‘Challenging’ in Real World
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Real-world application of sequencing for targeting pancreatic cancer treatment remains challenging, according to a study published in Clinical Cancer Research and presented at the American...
FDA Approves Roche’s KRAS Mutation Test
By Stephanie Murg, Managing Director, G2 Intelligence Roche's portfolio of companion diagnostics now includes a test that can help clinicians to tailor treatment for patients with metastatic colorectal cancer. The U.S. Food and Drug Administration has approved the...